Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could white blood cells drive skin scarring in scleroderma?

NCT ID NCT03816189

Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study examined whether eosinophils, a type of white blood cell, contribute to fibrosis (scarring) in systemic sclerosis, an autoimmune disease. Researchers compared blood samples from 40 patients with systemic sclerosis and 30 healthy volunteers, with optional skin biopsies. The goal was to understand how eosinophils might promote tissue damage, which could inform future treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could point toward new targets for treating fibrosis in systemic sclerosis.
What could go wrong
This is an observational study with only 70 participants, so findings may not apply broadly or lead directly to treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

70 people

The number who actually took part.

Started

Oct 2018

Finished

Apr 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The active line of the Internal Medicine department (\> 400 sclerodermic patients) guarantees the recruitment of 20 diffuse forms and 20 limited forms

Ages

18 to 66 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * For SSc patients: * Meeting the 2013 ACR-EULAR criteria for diffuse SSc (n = 20) and limited SSc (n = 20) * Having signed the informed consent * Eosinophils ≥ 0.1 G / L on the last blood test (\<3 months) For healthy subjects: * Without chronic pathology requiring long-term treatment * Eosinophils between 0.1 and 0.4 G / L on recent blood test (\<3 months) Exclusion Criteria for patients and controls: * Patient with an infection, state of emergency or progressive neoplastic pathology * Pregnant or lactating women * History of atopy (allergic asthma, atopic eczema, allergic rhinitis, allergic conjunctivitis) * Allergy to local anesthetics (for scleroderma patients only) * Taking into account a minimum weight of 50 kg and in the absence of cardiorespiratory effects of scleroderma, only patients with at least 10 g of hemoglobin will be included

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Systemic scleroderma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Fibrosis systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Systemic scleroderma Systemic sclerosis

Contacts and locations

Locations

  • Hôpital Claude Huriez, CHU

    Lille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.